Table 3

Polymorphisms in XRCC1 and breast cancer risk

Wild typeHeterozygoteHomozygous variant
C26304T (Arg194Trp)a
 Cases/controlsb890/1190105/1763/3
 Matched ORc1.000.81 (0.62–1.05)
 Multivariate ORd1.000.79 (0.60–1.04)
C26602Ta
 Cases/controlsb874/1229101/1376/2
 Matched ORc1.001.09 (0.83–1.43)
 Multivariate ORd1.001.09 (0.81–1.45)
G28152A (Arg399Gln)
 Cases/controlsb391/545460/616135/176
 Matched ORc1.001.06 (0.88–1.27)1.06 (0.81–1.39)
 Multivariate ORd1.001.07 (0.88–1.30)1.03 (0.77–1.37)
G36189A (Gln632Gln)
 Cases/controlsb340/444480/678160/232
 Matched ORc1.000.90 (0.75–1.09)0.89 (0.69–1.13)
 Multivariate ORd1.000.91 (0.75–1.11)0.90 (0.69–1.16)
  • a Heterozygote and homozygous variant are combined to compare with wild type.

  • b The number of participants does not sum to total women because of missing data on genotype.

  • c Conditional logistic regression adjusted for the matching variables: age; menopausal status; postmenopausal hormone use; date of blood draw; time of blood draw; and fasting status.

  • d Conditional logistic regression adjusted for the matching variables, BMI at age 18 years (continuous), weight gain since age 18 years (<5, 5–19.9, ≥20 kg), age at menarche (<12, 12, 13, >13 years), age at menopause (<45, ≥45 to <50, ≥50 to <55, or ≥55 years), parity/age at first birth (nulliparous, 1–2 children/age at first birth ≤24 years, 1–2 children/age at first birth >24 years, 3+ children/age at first birth ≤24 years, 3+ children/age at first birth >24 years), first-degree family history of breast cancer (yes/no), history of benign breast disease (yes/no), and duration of postmenopausal hormone use (never use, past use, current use <5 years, current use ≥5 years).